Dialysable leukocyte extracts in immunotherapy

References

• Fudenberg HH, Fudenberg HH. Transfer factor: past, present and future. Ann Rev Pharmacol Toxicol. 1989;29: 475–516.
   PubMed Web of Science ®Google Scholar
• Mikula I, Pistl J, Snirc J. Leukocyte dialysate in veterinary practice [in Slovak]. Slov Vet Cas. 1994;19(4):194–199.
   Google Scholar
• Sanchez-Gonzalez DJ, Sosa-Luna CA, Vasquez-Moctezuma I. Transfer factors in medical therapy [in Spanish]. Mеd Clin-Barcelona. 2011;137(6):273–277..
   PubMed Web of Science ®Google Scholar
• Lawrence HS. The transfer in human of delayed skin sensitivity to Streptococcal M substance and tuberculin with disrupts leucocytes. J Clin Investig. 1955;34:219–230.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick CH. Transfer factor: perspectives in human and veterinary medicine. J Exp Pathol. 1987;3(4):383– 398.
   PubMedGoogle Scholar
• Fudenberg HH, Pizza G. Transfer factor 1993: new frontiers. Prog Drug Res. 1994;42:309–400.
   PubMedGoogle Scholar
• Berron-Perez R, Chavez-Sanchez R, Estrada-Garcia I, et al. Indications, usage, and dosage of the transfer factor. Rev Alerg Mex. 2007;54(4):134–139.
   PubMedGoogle Scholar
• Krishnaveni M. A review on transfer factor an immune modulator. Drug Invent Today. 2013;5(2):153–156.
   Google Scholar
• Kirkpatrick CH. Structural nature and function of transfer factor. Ann NY Acad Sci. 1993;685(1):362–368.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick CH. Transfer factors: identification on conserved sequences in transfer factor molecules. Mol Med. 2000;6(4):332–341.
   PubMed Web of Science ®Google Scholar
• Sudhir KS, Sizemore RS, Gottlieb AA. Immunomodulatory components present in IMREG-1, an experimental immunosupportive biologic. Nat Biotechnol. 1988;6:810–815.
   Web of Science ®Google Scholar
• Klesius PH, Fudenberg HH, Smith CL. Comparative studies on dialyzable leukocyte extracts containing transfer factor— a review. Comp Immunol Microbiol Infect Dis. 1980;3(3):247–260.
   PubMed Web of Science ®Google Scholar
• Bai-Lai H. Clinical application of transfer factor in China. In: Mayer V, Borvak J, editors. Proceedings of Fifth International Symposium on Transfer Factor. 1986 Nov 10–13; Smolenice: SAS Bratislava; 1987.
   Google Scholar
• Grob PJ, Reymond JF, Hacki MA, et al. Some physico-chemical and biological properties of a transfer factor preparation and its clinical application. In: Ascher MS, Gottlieb AA, Kirkpatrick CH, editors. Proceedings of Second International Workshop on Basic Properties and Clinical Applications of Transfer Factor. 1975 Oct 5–8; Friderick (MD): New York Academic Press, 1976.
   Google Scholar
• Ashorn R, Uotila A, Kuokkanen K, et al. Cellular immunity in acne vulgaris during transfer factor treatment. Ann Clin Res. 1984;17(4):152–155.
   Google Scholar
• Mikula I, Pistl J. The use of mouse model for the determination of protective activity in Salmonella-specific leucocyte dialyzate. Acta Vet Brno. 1989;58(2):281–296.
   Web of Science ®Google Scholar
• Arnaudov A, Daskalova S. Physicochemical and immunological analysis of antisalmonella dialyzable leucocyte extracts [in Bulgarian]. Vet Med. 1997;3(1–2):46–49.
   Google Scholar
• Lawrence HS, Borkowsky W. Transfer factor – current status and future properties. Biotherapy. 1996;9:1–5.
   PubMedGoogle Scholar
• Gottlieb AA, Maziarz GA, Tamaki N, et al. The effects of dialyzable products from human leukocyte extracts on cutaneous delayed-hypersensitivity response. J Immunol. 1980;124(2):885–892.
   PubMed Web of Science ®Google Scholar
• Hromas J, Vacek A, Hofer M, et al. Hemopoiesis-stimulating effects and enhanced survival of irradiated mice after peroral or intraperitoneal administration of ultrafiltered pig leukocyte extract (UPLE, IMUNOR®). Immunopharmocology Immunotoxicology. 2002;24(4):651–664.
   PubMed Web of Science ®Google Scholar
• Franco-Molina MA, Mendoza-Gamboa E, Castillo-Tello P, et al. In vitro antibacterial activity of bovine dialyzable leukocyte extract. Immunopharmocology Immunotoxicology. 2006;28(3):471–483.
   PubMed Web of Science ®Google Scholar
• Ojeda MO, Van't Veer C, Fernández-Ortega CB, et al. Dialyzable leukocyte extract differentially regulates the production of TNFα, IL-6, and IL-8 in bacterial component-activated leukocytes and endothelial cells. Inflamm Res. 2005;54(2):74–81.
   PubMed Web of Science ®Google Scholar
• Robles-Contreras A, Vizuet L, Rivera E, et al. Down regulation of IL-8 and IL-6 in human limbal epithelial cells cultured with human dialyzable leukocyte extracts. Rev Alerg Mex. 2011;58:147–154.
   PubMedGoogle Scholar
• Roberto-Avila F, Wong-Baeza I, Serafin-Lopez J, et al. Human dialyzable leukocyte extracts (DLE) have ligands for TLR-2 but not for TLR-4 [Meeting Abstracts]. J Immunol. 2007;178:S89.
   Google Scholar
• García-Hernández U, Robledo-Avila FH, Alvarez-Jiménez VD, et al. Dialyzable leukocyte extracts activate TLR-2 on monocytes. Nat Prod Commun. 2014;9(6):853–856.
   PubMed Web of Science ®Google Scholar
• Burger DR, Vandenbark AA, Daves D, et al. Nicotinamide: suppression of lymphocyte transformation with a component identified in human transfer factor. J Immunol. 1976;117(3):797–801.
   PubMed Web of Science ®Google Scholar
• Viza D, Fudenberg HH, Palareti A, et al. Transfer factor: an overlooked potential for the prevention and treatment of infectious diseases. Folia Biol-Praha. 2013;59:53–67.
   PubMed Web of Science ®Google Scholar
• Robles-Contreras A, Rivera-Mendez E, Vizuet-Garcia L, et al. Dyalizable leukocyte extracts regulate the expression of HBD-2 and LL37 in human limbal epithelial cells [abstract]. Invest Ophthalmol Vis Sci. 2011;52(6):1121.
   Google Scholar
• Perepechkina NP, Perepechkin LP. Efficient molecular mass fractionation of leukocyte extract by membrane separation. J Membrane Sci. 1999;160(1):1–6.
   Web of Science ®Google Scholar
• Hernandez-Peralta P, Perez-Tapia SM, Limon-Flores AY, et al. Dialyzable leukocyte extract as inductor of interferon gamma concentration in serum of weaned pigs[in Spanish]. Archivos de Medicina Veterinaria. 2014;46(3):425–430.
   Web of Science ®Google Scholar
• Lara HH, Ixtepan-Turrent L, Garza-Treviño EN, et al. Antiviral mode of action of bovine dialyzable leukocyte extract against human immunodeficiency virus type 1 infection. BMC Res Notes. 2011;4(1):474–482.
   PubMedGoogle Scholar
• Xu YP, Zou WM, Zhan XJ, et al. Preparation and determination of immunological activities of anti-HBV egg yolk extraction. Cell Mol Immunol. 2006;3(1):67–71.
   PubMed Web of Science ®Google Scholar
• Hennen WJ, Lisonbee DT, inventors; US Patent and Trademark Office, assignee. Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use. United States patent US 6,468,534. 2002 Oct 22.
   Google Scholar
• Wilson GB, Poindexter C, Fort D, et al. De Novo initiation of specific cell-mediated immune responsiveness in chickens by transfer factor (specific immunity inducers) obtained from bovine colostrum and milk. Acta Virol. 1988;32:6–18.
   PubMed Web of Science ®Google Scholar
• Wilson GB, Paddock GV, inventors; Amtron, Inc., assignee. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof. United States patent US 4,816,563. 1989 Mar 28.
   Google Scholar
• Kirkpatrick CH, Greenberg LE, Petersen EA. Transfer factor. Lymphokines. 1983;8:1–39.
   Google Scholar
• Estrada-Parra S, Estrada-Garcia ICE, Pérez-Tapia SM, inventors; US Patent and Trademark Office, assignee. Method for obtaining a dialyzable leukocyte extract. United States patent US 20,140,357,840. 2014 Dec 4.
   Google Scholar
• Kirkpatrick CH. Activities and characteristics of transfer factors. Biotherapy. 1996;9:13–16.
   PubMedGoogle Scholar
• Pineda B, Estrada-Parra S, Pedraza-Medina B, et al. Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. J Exp Clin Cancer Res. 2005;24(4):575–583.
   PubMed Web of Science ®Google Scholar
• Franco-Molina MA, Mendoza-Gamboa E, Miranda-Hernandez D, et al. In vitro effects of bovine dialyzable leukocyte extract (bDLE) in cancer cells. Cytotherapy. 2006;8(4):408–414.
   PubMed Web of Science ®Google Scholar
• Fudemberg HH. Dialyzable transfer factor in the treatment of human osteosarcoma: an analytic review. Ann NY Acad Sci. 1976;277(1):545–557.
   PubMed Web of Science ®Google Scholar
• Juarez PC. Effect of Transferon® as an adjuvant in the treatment of osteosarcoma [in Spanish] [dissertation]. Mexico City: National Polytechnic Institute; 2011.
   Google Scholar
• Pizza G, De Vinci C, Cuzzocrea D, et al. A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Biotherapy. 1996;9:123–132.
   PubMedGoogle Scholar
• Pilotti V, Mastrorilli M, Pizza G, et al. Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy. 1996;9:117–121.
   PubMedGoogle Scholar
• Franco-Molina MA, Mendoza-Gamboa E, Zapata-Benavides P, et al. IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients. Cytotherapy. 2008;10:490–496.
   PubMed Web of Science ®Google Scholar
• Viza D, Lefesvre A, Patrasco M, et al. A preliminary report on three AIDS Patients treated with anti-HIV specific transfer factor. J Exp Pathol. 1987;3(4):653–659.
   PubMedGoogle Scholar
• Carey JT, Lederman MM, Toossi Z, et al. Augmentation of skin test reactivity and lymphocyte blastogenesis in patients with AIDS treated with transfer factor. JAMA. 1987;257(5):651–655.
   PubMed Web of Science ®Google Scholar
• Gottlieb MS, Zackin RA, Fiala M, et al. Response to treatment with the leukocyte-derived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex: a multicenter, double-blind, placebo-controlled trial. Ann Intern Med. 1991;115(2):84–91.
   PubMed Web of Science ®Google Scholar
• Gottlieb AA. Clinical and immunologic observations in patients with AIDS-related complex treated with IMREG-1. Int J Immun. 1991;13:29–32.
   PubMed Web of Science ®Google Scholar
• Pizza G, Chiodo F, Colangeli V, et al. Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy. 1996;9:41–47.
   PubMedGoogle Scholar
• Raise E, Guerra L, Viza D, et al. Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV). Biotherapy. 1996;9:49–54.
   PubMedGoogle Scholar
• Khan A, Hansen B, Hill NO, et al. Transfer factor in the treatment of herpes simplex types 1 and 2. Dermatology. 1981;163(2):177–185.
   Google Scholar
• Steele RW, Myers MG, Vincent MM. Transfer factor for the prevention of varicella-zoster infection in childhood leukemia. New England J Med. 1980;303(7):355–359.
   PubMed Web of Science ®Google Scholar
• Bowden RA, Siegel MS, Steele RW, et al. Immunologic and clincal responses to Varicella-Zoster virus-specific transfer factor following marrow transplantation. J Infect Dis. 1985;152:1324–1327.
   PubMed Web of Science ®Google Scholar
• Estrada-Parra S, Nagaya A, Serrano E, et al. Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Int J Immunopharmacol. 1998;20(10):521– 535.
   PubMed Web of Science ®Google Scholar
• Pizza G, Viza D, Roda A, et al. Transfer factor for the treatment of chronic acute hepatitis. New Eng J Med. 1979;300 (23):1332–1332.
   PubMed Web of Science ®Google Scholar
• Roda E, Viza D, Pizza G, et al. Transfer factor for the treatment of HbsAg-positive chronic active hepatitis. Exp Biol Med. 1985;178(3):468–475.
   Web of Science ®Google Scholar
• Whitcomb ME, Rocklin RE. Transfer factor therapy in a patient with progressive primary tuberculosis. Ann Intern Med. 1973;79(2):161–166.
   PubMed Web of Science ®Google Scholar
• Vidal L, Palafox D. Transfer factor may provide immunomodulation in cutaneous tuberculosis. Poster session presented at: WAO Symposium on Immunotherapy and Biologics; 2014 Dec 13–14; Chicago, IL.
   Google Scholar
• Fabre RA, Pérez TM, Aguilar LD, et al. Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis. Clin Exp Immunol. 2004;136(2):215–223.
   PubMed Web of Science ®Google Scholar
• Masi M, De Vici C, Baricordi OR. Transfer factor in chronic mucocutaneous candidiasis. Biotherapy. 1996;9: 97–103.
   PubMedGoogle Scholar
• Graybill JR, Silva J, Alford RH, et al. Immunologic and clinical improvement of progressive coccidioidomycosis following administration of transfer factor. Cell Immunol. 1973;8(1):120–135.
   PubMed Web of Science ®Google Scholar
• Catanzaro A, Spitler L, Moser KM. Immunotherapy of coccidioidomycosis. J Clin Invest. 1974;54(3):690–701.
   PubMed Web of Science ®Google Scholar
• Santacruz-Valdes C, Aguilar G, Perez-Tapia M, et al. Dialyzable leukocyte extracts (Transfer factor) as adjuvant therapy for fungal keratitis. Am J Case Rep. 2010; 11:97–101.
   Google Scholar
• Delgado O, Romano EL, Belfort E, et al. Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis. Clin Immunol Immunop. 1981;19(3):351–359.
   PubMedGoogle Scholar
• Dvorožňáková, Porubcová J, Ševčíková Z. Immune response of mice with alveolar echinococcosis to therapy with transfer factor, alone and in combination with albendazole. Parasitol Res. 2009;105(4):1067–1076.
   PubMed Web of Science ®Google Scholar
• Homberg TA, Lara RI, Pérez-Tapia SM, et al. Dialyzable leukocyte extracts as adjuvant treatment for allergic rhinitis. Poster session presented at: WAO Symposium on Immunotherapy and Biologics; 2014 Dec 13–14; Chicago, IL.
   Google Scholar
• García AE, Carreón JG, Ramírez E, et al. Randomized clinical trial to evaluate oral dializable leukocyte extracts as immunemodulator treatment in atopic dermatitis. Poster session presented at: WAO Symposium on Immunotherapy and Biologics; 2014 Dec 13–14; Chicago, IL.
   Google Scholar
• Homberg T, Sáenz V, Galicia-Carreón J, et al. The adverse event profile in patients treated with Transferon TM (Dialyzable leukocyte extracts): A preliminary report. Pharmacol Pharm. 2015;6(2):65–74.
   Google Scholar
• Liburd EM, Pabst HF, Armstrong WD. Transfer factor in rat coccidiosis. Cell Immunol. 1972;5(3):487–489.
   PubMed Web of Science ®Google Scholar
• Klesius PH, Kristensen F. Bovine transfer factor: effect on bovine and rabbit coccidiosis. Clin Immunol Immunopathology. 1977;7(2):240–252.
   PubMedGoogle Scholar
• Klesius PH, Giambrone JJ. Adoptive transfer of delayed hypersensitivity and protective immunity to Eimeria tenella with chicken-derived transfer factor. Poult Sci. 1984;63(7):1333–1337.
   PubMed Web of Science ®Google Scholar
• Smith RA, Esa A, Stiff M. Transfer of Salmonella resistance and delayed hypersensitivity with murine-derived transfer factor. Infect Immun. 1982;36(1):271–276.
   PubMed Web of Science ®Google Scholar
• Mikula I, Pistl J, Rosocha J. Dialyzable leukocyte extract used in the prevention of Salmonella infection in calves. Vet Immunol Immunop. 1992;32(1):113–124.
   PubMed Web of Science ®Google Scholar
• Arnaudov A, Tziporkov N. Some properties and protective activity of specific DLE against Salmonella cholerae suis infection. Biotherapy. 1996;9:105–108.
   PubMedGoogle Scholar
• Arnaudov A. A study on the protective action of Salmonella-specific dialysable leukocyte extract. Folia Vet. 2000;44(2):76–79.
   Google Scholar
• Kokincakova T, Herich R, Levkutova M. Effect of application of dialysable leukocyte extract on experimental salmonellosis in chickens. Folia Veterinaria. 2008;1:36–37.
   Google Scholar
• Bravo-Blas A, Tellez R, Uribe S, et al. Transfer factor acting as IFN-gamma and IL-2 mRNA expression inductor in chicken vaccinated against avian influenza. Archivos de Medicina Veterinaria. 2010;42(1):67–71.
   Web of Science ®Google Scholar